Ergebnis der Suchanfrage nach Rö
Inhalte
- Kategorie:
- Sprache:
-
Medien:
Alle
- Zeitraum:
- Zeitraum:Gesamt
- mehr
LAUDA DR. R. WOBSER GMBH & CO. KG
LAUDA honors Theo Schlegelmilch for 40 years with the company
mehrNew Cybersecurity Check for Real-Time Operating Systems (RTOS)
New Cybersecurity Check for Real-Time Operating Systems (RTOS) - Real-time operating systems (RTOS) run billions of devices and are potential targets for hackers because their cyber resilience has been almost impossible to test. - CEO Jan Wendenburg: "Our new RTOS component analysis and cybersecurity check is a real benefit for every manufacturer in the embedded industry. Duesseldorf, 18 February 2025 – Checking ...
mehrLAUDA DR. R. WOBSER GMBH & CO. KG
2LAUDA supports young scientists at the University of Würzburg
mehrStudy: Industry Should Make Cybersecurity a Top Priority for Devices, Machines, and Systems in 2025
Study: Industry Should Make Cybersecurity a Top Priority for Devices, Machines, and Systems in 2025 - “OT+IoT Cybersecurity Report”: Companies have too little budget for cybersecurity - Jan Wendenburg, CEO ONEKEY: “Companies should be prepared for cyber incidents.” - ONEKEY at Embedded World 2025: Hall 5, ...
mehrLAUDA DR. R. WOBSER GMBH & CO. KG
Highest Honor for Fritz Bartelt: LAUDA awards Dr.-Rudolf-Wobser-Medal to Austrian corporate partner
mehr
DYMO PARTNERS WITH GA INTERNATIONAL (LABTAG) TO OFFER CRYOGENIC LABELS FOR DYMO LABELWRITER 5 SERIES PRINTERS
mehrExpert Warns: Smart Connected Devices Must Comply With The EU’s New Cyber Resilience Act
Expert Warns: Smart Connected Devices Must Comply With The EU’s New Cyber Resilience Act - "In future, smart-connected devices must comply with the new EU Cyber Resilience Act. Otherwise, it will be illegal to sell them in the European Union. Manufacturers face fines of up to 15 million euros or 2.5 per cent of their annual global turnover," reminds Jan Wendenburg, ...
mehrBosch Healthcare Solutions GmbH
Vivalytic Bacterial Meningitis by Bosch: PCR rapid test for medical emergencies
mehrGrünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer
mehrNorgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...
mehrLAUDA DR. R. WOBSER GMBH & CO. KG
Dr. Stefanie Krieger Managing Director of LAUDA Medical
mehr
LAUDA DR. R. WOBSER GMBH & CO. KG
Antonio Manconi Ten Years With LAUDA Italia
mehrLAUDA DR. R. WOBSER GMBH & CO. KG
LAUDA World Market Leader for the Ninth Time
mehr20 Percent of Companies Fail to Conduct Cybersecurity Audits
20 Percent of Companies Fail to Conduct Cybersecurity Audits Building Cybersecurity Awareness: Empowering Workforces to Tackle Cyberattacks and Threats Duesseldorf, December 11 2024 – 40 percent of industrial companies in Germany provide regular cybersecurity education and training for their employees, while 27 percent include cybersecurity rules and procedures in their employee handbooks and company policies. “That ...
mehrTechnische Universität München
Removing hazardous PFAS chemicals from drinking water
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE TUM researchers develop highly effective filter material Removing hazardous PFAS chemicals from drinking water - Metal-organic framework compounds made of zirconium carboxylate as filters - Large-scale use in practice still to come - Contaminated sites caused by PFAS will be with us for several generations ahead The chemicals known as PFAS are considered a severe threat to ...
mehrReminder: canSERV Call for Service Provision "Training the Next Generation of Cancer Researchers"
Ein DokumentmehrExperts Warn of Cybersecurity Risks in Open-Source Software
Experts Warn of Cybersecurity Risks in Open-Source Software Manufacturers of connected devices, machines, and systems that use open-source software face an exceptionally high risk. Duesseldorf, 21 November 2024 – Manufacturers of connected devices, machines, and systems must be particularly vigilant when using open-source software in their products under the new EU Cyber Resilience Act (CRA). Although open-source ...
mehr
PM: Globalisierung bleibt auf Rekordniveau, trotz geopolitischer Spannungen und Unsicherheit / PR: Globalization remains at a record level, despite geopolitical tensions and uncertainties
mehrNew Project DCDYNAMIC Advances Cable Technology for Greener Power Grid
mehrLast Call for canSERV Third Open Call Funding
Ein DokumentmehrLAUDA DR. R. WOBSER GMBH & CO. KG
4LAUDA Doubles Production Area in China
mehrReport Reveals: Industry Exposes Itself to Cybersecurity Risks
Report Reveals: Industry Exposes Itself to Cybersecurity Risks - The digitalisation of manufacturing and logistics introduces unknown software vulnerabilities that hackers can exploit. - ONEKEY’s “OT+IoT Cybersecurity Report” reveals: Smart factories are often insufficiently protected. Duesseldorf, November 7 2024 – German industry is increasingly exposing itself to security vulnerabilities due to the ongoing ...
mehrLAUDA DR. R. WOBSER GMBH & CO. KG
40th work anniversary at the world market leader
mehr
LAUDA DR. R. WOBSER GMBH & CO. KG
LAUDA honors Rainer Deinert for 45 years of company loyalty
mehrCyber Resilience Act Passed – A Paradigm Shift in Product Cybersecurity
Cyber Resilience Act Passed – A Paradigm Shift in Product Cybersecurity Jan Wendenburg: “The Cyber Resilience Act was passed by the EU Council on October 10th, making cybersecurity mandatory for all manufacturers. Connected devices must be designed to remain protected against cyberattacks with up-to-date software throughout their entire lifecycle.” Duesseldorf, ...
mehrLAUDA DR. R. WOBSER GMBH & CO. KG
Dr. Marc Stricker with LAUDA for ten years
mehrFirst participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
mehrLAUDA DR. R. WOBSER GMBH & CO. KG
3Honey from Own Bee Colonies
mehrPOWERBASE facilitates green transition of emergency response organisations
mehr